Skip to main content
. Author manuscript; available in PMC: 2007 Dec 5.
Published in final edited form as: Arthritis Rheum. 2007 Jan;56(1):280–290. doi: 10.1002/art.22306

Figure 2.

Figure 2

Binding of polyclonal IgG from patients with antiphospholipid syndrome (APS) to mutant recombinant human domain I in the solid phase. A panel of purified IgG samples derived from 10 patients with APS was selected. Enhanced binding as compared with wild-type recombinant human domain I was greatest with the domain I mutant in which both D residues were mutated (Mut 8+9) and the extended domain I (DI ext) mutant. The greatest reduction in binding compared with wild-type domain I was observed with the single-point D8 and D9 mutants and the R39 mutant. Bars show the mean.